Supplementary Data 3 from Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
Espen B. Ellingsen(Oslo University Hospital), Yousef Zakharia(University of Iowa), Artur Mezheyeuski(Uppsala University), Steven O’Day(Saint John's Health Center), Trevor Clancy(Inholland University of Applied Sciences), Timothy S. Kristedja(Saint John's Health Center), Mohammed Milhem(University of Iowa), Agnieszka Gromadka(Institute of Biochemistry and Biophysics, Polish Academy of Sciences)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594